article thumbnail

FDA Approves Abbott's Novel Dissolvable Stent Therapy for Peripheral Artery Disease

HCPLive

Abbott's Esprit BTK System was shown to significantly reduce risk of ischemic events in patients with PAD versus angioplasty over 1 year.

article thumbnail

Comparison of Noncompliant Balloon With Drug-Coating Balloon Angioplasties for Side Branch After Provisional Stenting for Patients With True Coronary Bifurcation Lesions

American College of Cardiology

The goal of the DCB-BIF trial was to assess the efficacy of drug-coated balloon (DCB) angioplasty of residual side branch stenosis in coronary bifurcation lesions treated with a provisional stenting strategy.

article thumbnail

Resorbable stent vs. angioplasty safety outcomes: 5 study notes

Becker's Hospital Review - Cardiology

A drug-eluting resorbable stent was found to be just as effective in treating infrapopliteal artery disease in patients at risk of limb amputation, according to a study published Oct. 25 in the New England Journal of Medicine.

Stents 52
article thumbnail

ECLIPSE: Orbital Atherectomy vs. Conventional Balloon Angioplasty Prior to DES Implantation

American College of Cardiology

The routine use of orbital atherectomy did not improve minimal stent area (MSA) or reduce target vessel failure (TVF) at one year compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent (DES) in severely calcified coronary lesions.

article thumbnail

Rotarex®S rotational atherectomy combined with drug-coated balloon angioplasty for treating femoropopliteal artery in-stent restenosis

Journal of Cardiothoracic Surgery

This study aimed to analyze the safety and mid-term outcomes of a hybrid treatment method combining rotational atherectomy (RA) with drug-coated balloon (DCB) angioplasty in patients with femoropopliteal arter.

article thumbnail

REC-CAGEFREE I: DCB Angioplasty With Rescue Stenting vs. Intended DES in Patients With de novo Noncomplex Coronary Artery Lesions

American College of Cardiology

A strategy of drug-coated balloon (DCB) angioplasty with rescue stenting did not achieve noninferiority compared with intended drug-eluting stent (DES) deployment for patients with de novo, noncomplex coronary artery lesions, according to finding from the REC-CAGEFREE I trial presented at ESC Congress 2024 in London and simultaneously published in (..)

article thumbnail

Drug-Coated Balloons for the Treatment of CAD

JAMA Cardiology

This narrative review discusses drug-coated balloon angioplasty as an alternative to drug-eluting stent for percutaneous coronary intervention in patients with in-stent restenosis and de novo coronary artery disease.